MEDIPOST requests approval for the phase 2 clinical trial in Korea of its next-generation injectable drug for knee osteoarthritis, SMUP-IA-012021/07/30STEM CELL THERAPEUTIC
MEDIPOST presents the development progress of its next-generation injectable drug for knee osteoarthritis in the Spring Conference of the Korean Orthopedic Surgeons Association2021/07/09STEM CELL THERAPEUTIC
MEDIPOST completes the expansion of its GMP facilities for CARTISTEM, a stem cell therapy, and SMUP-IA-01, an injectable knee osteoarthritis treatment2021/05/17STEM CELL THERAPEUTIC
MEDIPOST’s phase 1 clinical trial results for its injectable drug for knee osteoarthritis in Korea show improvements in safety and clinical symptoms2021/03/22STEM CELL THERAPEUTIC
MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia2021/03/15STEM CELL THERAPEUTIC
MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan2021/02/15STEM CELL THERAPEUTIC
MEDIPOST completes the phase 1 clinical trial of its injectable drug for knee osteoarthritis, SMUP-IA-012020/11/16STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/07/07STEM CELL THERAPEUTIC
MEDIPOST’s Clinical Trial of Next-Generation Cell Therapy Product ‘SMUP-IA-01’ Makes Solid Progress2020/05/21STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 2a Clinical Trial of NEUROSTEM for Alzheimer’s Disease2020/01/06STEM CELL THERAPEUTIC
MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan2019/12/09STEM CELL THERAPEUTIC
